active bacterial or fungal infection, human immunodeficiency virus (hiv), hhv, epstein-barr virus, or other non-respiratory virus infection, or tuberculosis requiring initiation of anti-infective therapy prior treatment with an agent targeting the il-6 signaling pathway current treatment in another therapeutic clinical trial (other than expanded remdesivir access protocol) start of new immunosuppressive therapy (including but not limited to corticosteroids and cytokine signaling pathway inhibitors) within 4 days prior to study entry (randomization); start of new antiviral treatment (including but not limited to nucleoside analogues, aminoquinoline compounds, and convalescent plasma) within 2 days prior to randomization; or received a live vaccine at any time prior to randomization, or plan to receive a live vaccine during the study

active bacterial or fungal infection, human immunodeficiency virus (hiv), hhv, epstein-barr virus, or other non-respiratory virus infection, or tuberculosis requiring initiation of anti-infective therapy prior treatment with an agent targeting the il-6 signaling pathway current treatment in another therapeutic clinical trial (other than expanded remdesivir access protocol) start of new immunosuppressive therapy (including but not limited to corticosteroids and cytokine signaling pathway inhibitors) within 4 days prior to study entry (randomization); start of new antiviral treatment (including but not limited to nucleoside analogues, aminoquinoline compounds, and convalescent plasma) within 2 days prior to randomization; or received a live vaccine at any time prior to randomization, or plan to receive a live vaccine during the study